TRAZIMERA is a biosimilar to the original biologic medication, trastuzumab, which is widely used in the treatment of certain types of breast cancer and gastric cancer. It is specifically designed for cancers that overexpress the HER2/neu receptor, a protein that promotes the growth of cancer cells. By targeting and inhibiting the function of this receptor, TRAZIMERA helps in slowing down or stopping the growth of cancer cells. As a biosimilar, TRAZIMERA has been rigorously tested to ensure it is highly similar to its reference product, trastuzumab, in terms of safety, purity, and potency. It is administered through intravenous infusion and is often used in combination with other cancer treatments as part of a comprehensive cancer therapy plan.